STAT March 15, 2024
Meghana Keshavan

Hey there. Today, we see the first approval of a drug to treat MASH, a Gilead medication shows huge promise in Ebola, and more.

The need-to-know this morning

  • Bristol Myers Squibb won FDA approval to expand the use of its Breyanzi CAR-T treatment to include patients with chronic lymphocytic leukemia. Breyanzi, already approved for lymphoma, is the first personalized cell therapy to receive an additional regulatory clearance to treat this type of blood cancer.

Madrigal wins first approval for MASH drug

The FDA yesterday granted an accelerated approval for the first medicine to treat MASH. The pill, made by Madrigal Pharmaceuticals, is called Rezdiffra. MASH is a serious liver disease that is linked to obesity and causes inflammation...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
Zealand Pharma, Roche Reach Potential $5.3 Billion Deal to Develop Petrelintide for Weight Management
STAT+: Pharmalittle: We’re reading about a Roche deal for an obesity drug, a Gilead HIV drug and more
Roche builds in obesity with $5.3bn Zealand licensing deal
Roche Puts Up $1.65B to Partner With Zealand on ‘Future Foundational Therapy’ for Obesity
Ono pays $280M to license Ionis rare disease drug

Share This Article